7.12 Extension of Term of Standard Patents Relating to Pharmaceutical Substances

Date Published

Processing of Extension of Term applications has been temporarily paused while we consider the decision in Otsuka Pharmaceuticals Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161.

In this topic:

Relevant Legislation

The Act

The Regulations

Overview

Requirements for Obtaining an Extension of Term

Rights of Patentee During the Extended Term​​​​​​​


Relevant Legislation

The Act

Section 70Applications for extension of patent
Section 71Form and timing of an application
Section 74Acceptance or refusal of application
Section 75Opposition to grant of extension
Section 76Grant of extension
Section 77Calculation of term of extension
Schedule 1Dictionary

The Regulations

Regulation 6.8Information to accompany application

Overview

The Intellectual Property Laws Amendment Act 1998 amended the Patents Act 1990 to provide for an extension of term for pharmaceutical patents. The scheme allows patentees to apply for an extension of term of up to 5 years for a standard patent that claims a pharmaceutical substance.

Requirements for Obtaining an Extension of Term

In order to obtain an extension of term for a patent, the following requirements must be met:

  • the patent must, in substance, disclose and claim a pharmaceutical substance per se, or a pharmaceutical substance when produced by recombinant DNA technology;
  • goods containing or consisting of that pharmaceutical substance must be included in the Australian Register of Therapeutic Goods (ARTG); and
  • the first regulatory approval for that pharmaceutical substance must have occurred more than 5 years after the date of the patent.

Provided the requirements of the Act are satisfied, the term of the patent (in its entirety) may be extended.

Rights of Patentee During the Extended Term

The rights of a patentee during the extended term of a patent are however limited over the normal rights in a patent. Although the term of the patent as a whole is extended, exploitation of any form of the invention that is not a pharmaceutical substance and exploitation of pharmaceutical substances for non­therapeutic uses do not constitute infringement of the patent during the extended term (s78).

Amended Reasons

Amended Reason Date Amended

Amended wording of suspension of EoT applications to be more consistent with other pages in volume 7.

Added banner to indicate EoT have been suspended.

Back to top